Pharm-Olam selected to support Revive Therapeutics development of Bucillamine for COVID-19

Revive Therapeutics Ltd. is pleased to announce that the Company has retained Pharm-Olam, LLC, as CRO to advance the future clinical study for Bucillamine in the treatment of coronavirus disease (“COVID-19”).